Purple Biotech (PPBT) vs Sunshine Biopharma (SBFM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Purple Biotech is the larger company by market cap ($2.3 million vs $1.9 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PPBT | SBFM |
|---|---|---|
| Share price | $1.44 | $0.43 |
| Market cap | $2.34M | $1.85M |
| 1-day change | -1.37% | -38.57% |
| Forward P/E | — | 0.00 |
| EPS (TTM) | $-47.64 | $-9.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.10 | $24.30 |
| 52-week low | $1.16 | $0.356 |
| Distance from 52-week high | -89.79% | -98.23% |
| Analyst consensus | none | none |
| Avg. price target upside | +1080.56% | +12923.26% |
| Average volume | 1.28M | 5.25M |
| Shares outstanding | 1.63M | 4.31M |
| Employees | 10 | 50 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Purple Biotech
PPBT stock →Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and CAPTN-3 - IM1240 and IM1305, multi-valent antibody designed to activate anti-tumoral immune response against TAA positive tumors, which is in preclinical stage.
Healthcare · Biotechnology · 10 employees
About Sunshine Biopharma
SBFM stock →Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada.
Healthcare · Drug Manufacturers - Specialty & Generic · 50 employees
PPBT vs SBFM FAQ
Which is bigger, Purple Biotech or Sunshine Biopharma?
Purple Biotech (PPBT) is larger, with a market capitalization of $2.34M compared with $1.85M for Sunshine Biopharma (SBFM).
Are Purple Biotech and Sunshine Biopharma in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for Purple Biotech and Drug Manufacturers - Specialty & Generic for Sunshine Biopharma.